Cargando…
Drug Repositioning with GraphSAGE and Clustering Constraints Based on Drug and Disease Networks
The understanding of therapeutic properties is important in drug repositioning and drug discovery. However, chemical or clinical trials are expensive and inefficient to characterize the therapeutic properties of drugs. Recently, artificial intelligence (AI)-assisted algorithms have received extensiv...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127467/ https://www.ncbi.nlm.nih.gov/pubmed/35620297 http://dx.doi.org/10.3389/fphar.2022.872785 |
_version_ | 1784712358727254016 |
---|---|
author | Zhang, Yuchen Lei, Xiujuan Pan, Yi Wu, Fang-Xiang |
author_facet | Zhang, Yuchen Lei, Xiujuan Pan, Yi Wu, Fang-Xiang |
author_sort | Zhang, Yuchen |
collection | PubMed |
description | The understanding of therapeutic properties is important in drug repositioning and drug discovery. However, chemical or clinical trials are expensive and inefficient to characterize the therapeutic properties of drugs. Recently, artificial intelligence (AI)-assisted algorithms have received extensive attention for discovering the potential therapeutic properties of drugs and speeding up drug development. In this study, we propose a new method based on GraphSAGE and clustering constraints (DRGCC) to investigate the potential therapeutic properties of drugs for drug repositioning. First, the drug structure features and disease symptom features are extracted. Second, the drug–drug interaction network and disease similarity network are constructed according to the drug–gene and disease–gene relationships. Matrix factorization is adopted to extract the clustering features of networks. Then, all the features are fed to the GraphSAGE to predict new associations between existing drugs and diseases. Benchmark comparisons on two different datasets show that our method has reliable predictive performance and outperforms other six competing. We have also conducted case studies on existing drugs and diseases and aimed to predict drugs that may be effective for the novel coronavirus disease 2019 (COVID-19). Among the predicted anti-COVID-19 drug candidates, some drugs are being clinically studied by pharmacologists, and their binding sites to COVID-19-related protein receptors have been found via the molecular docking technology. |
format | Online Article Text |
id | pubmed-9127467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91274672022-05-25 Drug Repositioning with GraphSAGE and Clustering Constraints Based on Drug and Disease Networks Zhang, Yuchen Lei, Xiujuan Pan, Yi Wu, Fang-Xiang Front Pharmacol Pharmacology The understanding of therapeutic properties is important in drug repositioning and drug discovery. However, chemical or clinical trials are expensive and inefficient to characterize the therapeutic properties of drugs. Recently, artificial intelligence (AI)-assisted algorithms have received extensive attention for discovering the potential therapeutic properties of drugs and speeding up drug development. In this study, we propose a new method based on GraphSAGE and clustering constraints (DRGCC) to investigate the potential therapeutic properties of drugs for drug repositioning. First, the drug structure features and disease symptom features are extracted. Second, the drug–drug interaction network and disease similarity network are constructed according to the drug–gene and disease–gene relationships. Matrix factorization is adopted to extract the clustering features of networks. Then, all the features are fed to the GraphSAGE to predict new associations between existing drugs and diseases. Benchmark comparisons on two different datasets show that our method has reliable predictive performance and outperforms other six competing. We have also conducted case studies on existing drugs and diseases and aimed to predict drugs that may be effective for the novel coronavirus disease 2019 (COVID-19). Among the predicted anti-COVID-19 drug candidates, some drugs are being clinically studied by pharmacologists, and their binding sites to COVID-19-related protein receptors have been found via the molecular docking technology. Frontiers Media S.A. 2022-05-10 /pmc/articles/PMC9127467/ /pubmed/35620297 http://dx.doi.org/10.3389/fphar.2022.872785 Text en Copyright © 2022 Zhang, Lei, Pan and Wu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhang, Yuchen Lei, Xiujuan Pan, Yi Wu, Fang-Xiang Drug Repositioning with GraphSAGE and Clustering Constraints Based on Drug and Disease Networks |
title | Drug Repositioning with GraphSAGE and Clustering Constraints Based on Drug and Disease Networks |
title_full | Drug Repositioning with GraphSAGE and Clustering Constraints Based on Drug and Disease Networks |
title_fullStr | Drug Repositioning with GraphSAGE and Clustering Constraints Based on Drug and Disease Networks |
title_full_unstemmed | Drug Repositioning with GraphSAGE and Clustering Constraints Based on Drug and Disease Networks |
title_short | Drug Repositioning with GraphSAGE and Clustering Constraints Based on Drug and Disease Networks |
title_sort | drug repositioning with graphsage and clustering constraints based on drug and disease networks |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127467/ https://www.ncbi.nlm.nih.gov/pubmed/35620297 http://dx.doi.org/10.3389/fphar.2022.872785 |
work_keys_str_mv | AT zhangyuchen drugrepositioningwithgraphsageandclusteringconstraintsbasedondruganddiseasenetworks AT leixiujuan drugrepositioningwithgraphsageandclusteringconstraintsbasedondruganddiseasenetworks AT panyi drugrepositioningwithgraphsageandclusteringconstraintsbasedondruganddiseasenetworks AT wufangxiang drugrepositioningwithgraphsageandclusteringconstraintsbasedondruganddiseasenetworks |